Boston, MA 02/13/2014 (wallstreetpr) – Palatin Technologies, Inc. (NYSEMKT:PTN) the US-origin bio pharmaceutical company is expected to come under the scanner on Tuesday, Feb 18, 2014, when it will provide report of the fiscal year 2014.
Palatin Technologies, Inc. (NYSEMKT:PTN) is expected to make the announcement at a conference call as well as audio webcast on the same day. The schedule for the same indicates the executives will provide the financial results for the second quarter of 2014 and will take questions from analysts and investors.
Palatin Technologies, Inc. (NYSEMKT:PTN) which uses biotechnology for the development of drugs which are seen as wellness enhancers especially for the women population. Female Dysfunctions are addressed by the drugs which this company produces and is soon to commence Phase 3 testing of the same. Incidentally, the drug related to treating dysfunctionality in women is believed to be the most popular of all the drugs, this pharmacologist produces. The focus of the enhancement drugs is in being able to manage the severity of the dysfunction over cure.
Palatin Technologies, Inc. (NYSEMKT:PTN) in addition has three more drugs which are expected to provide therapy for over 5 diseases. These three other drugs, which are essentially receptor-specific therapies where the peptides are targeted, are expected to offer effective relief.
Palatin Technologies, Inc. (NYSEMKT:PTN) has adopted the -develop and collaborate -model of business. Palatin is known to develop products aimed at various diseases for therapeutic cure. Once a product is developed, it will then look for marketers who will remain the marketing collaborators. The key for PTN has been its success at finding the perfect industry leader and ensuring highest commercialization of tits products.
Palatin Technologies, Inc. (NYSEMKT:PTN) line of approach to develop the therapies is the use of receptor-specific peptide therapies which treat diseases which have unmet medical need and are known to hold great commercial potential.
